Tin tức & Cập nhật

Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC
Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC
16 Aug 2023

In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.

Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC
16 Aug 2023
Metabolic syndrome carries increased risk of lung cancer
Metabolic syndrome carries increased risk of lung cancer
15 Aug 2023

Individuals with metabolic syndrome (MetS) have a heightened risk of incident lung cancer, with the risk increase especially pronounced in those with a higher number of metabolic abnormalities and in women, according to a study.

Metabolic syndrome carries increased risk of lung cancer
15 Aug 2023
Real-world data: High rates of complications and unplanned hospital admissions in mHSPC
Real-world data: High rates of complications and unplanned hospital admissions in mHSPC
15 Aug 2023 bởiChristina Lau

Seventy percent of patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease-related complications, while 59 percent require ≥1 unplanned hospital admission during the course of disease, a study by the Chinese University of Hong Kong (CUHK) has shown.

Real-world data: High rates of complications and unplanned hospital admissions in mHSPC
15 Aug 2023